Therapeutic Potential of Laminin–Biodritin Microcapsules for Type 1 Diabetes Mellitus
Open Access
- 1 February 2015
- journal article
- Published by SAGE Publications in Cell Transplantation
- Vol. 24 (2) , 247-261
Abstract
Pancreatic islet microencapsulation constitutes an attractive therapy for type 1 diabetes mellitus; however, long-term β-cell function remains a major problem. Loss of extracellular matrix interactions during islet isolation dramatically affects β-cell viability. We have previously shown beneficial effects of laminin (LN) in human islet cultures. Herein, we investigated whether LN could improve the outcome of transplantation after islet microencapsulation in Biodritin, an alginate-based material. To test LN-Biodritin stability, microcapsules were subjected to different types of in vitro stress. Focusing on biocompatibility, empty microcapsules were coincubated with the RAW 264.7 macrophage cell line for up to 24 h, and empty beads were implanted IP in mice and retrieved for analyses after 7 and 30 days. Upon culturing for 48 h, mRNA, protein levels, and caspase 3 activity were evaluated in islets microencapsulated with LN-Biodritin. Mice rendered diabetic by streptozotocin injection were transplanted with microencapsulated islets, followed by assessment of body weight, glycemia, and graft function (evaluated by OGTT). Graft efficiency was observed upon microencapsulated islet explantation. The results obtained showed that LN-Biodritin microcapsules were as stable and biocompatible as Biodritin. Modulation of mRNA and protein levels suggested protection against apoptosis and islet stress. Mice transplanted with LN-Biodritin microencapsulated islets presented a better outcome at 198 days postsurgery. Graft explantation led animals to hyperglycemia. In conclusion, LN-Biodritin constitutes a very promising biomaterial for islet transplantation.Keywords
This publication has 68 references indexed in Scilit:
- Proliferation and plasticity of human beta cells on physiologically occurring laminin isoformsMolecular and Cellular Endocrinology, 2012
- Long-Term Metabolic and Immunological Follow-Up of Nonimmunosuppressed Patients With Type 1 Diabetes Treated With Microencapsulated Islet AllograftsDiabetes Care, 2011
- Immunoisolation of Pancreatic Islet Grafts with No Recipient’s Immunosuppression: Actual and Future PerspectivesCurrent Diabetes Reports, 2011
- Regulated laminin‐332 expression in human islets of LangerhansThe FASEB Journal, 2009
- Biodritin Microencapsulated Human Islets of Langerhans and Their Potential for Type 1 Diabetes Mellitus TherapyTransplantation Proceedings, 2008
- Monitoring of the islet graftDiabetes & Metabolism, 2006
- Inflammation-mediated dysfunction and apoptosis in pancreatic islet transplantation: implications for intrahepatic graftsJournal of Leukocyte Biology, 2005
- Tissue Factor and CCL2/Monocyte Chemoattractant Protein-1 Released by Human Islets Affect Islet Engraftment in Type 1 Diabetic RecipientsThe Journal of Clinical Endocrinology & Metabolism, 2004
- Importance of cell-matrix interactions in rat islet beta-cell secretion in vitro: role of alpha6beta1 integrin.Diabetes, 2000
- BCL-2 FAMILY: Regulators of Cell DeathAnnual Review of Immunology, 1998